MEMPHASYS LIMITED. — Capital/Financing Update 2022

Aug 28, 2022

ASX ANNOUNCEMENT

ASX: MEM

==> picture [187 x 51] intentionally omitted <==

29 August 2022

NON-RENOUNCEABLE ENTITLEMENT OFFER – DISPATCH OF PROSPECTUS

Australian-based bio-separations and reproductive biotechnology company Memphasys Limited (ASX: MEM) ( Company or Memphasys ) advises that it has completed the dispatch of the Prospectus in respect of the pro rata non-renounceable entitlement offer of one (1) new share for every 9 shares held by eligible shareholders on the record date (5pm AEST Wednesday 24 August 2022), at an issue price of 2 cents per Share, to raise up to $1.76 million ( Entitlement Offer ).

Further details of the Entitlement Offer, including details on how to accept the Entitlement Offer and key risks associated with an investment in the Company are set out in the Prospectus at - - https://www.memphasys.com/investor relations/asx announcements/. Applications for new Shares under the Entitlement Offer may only be made by following the instructions on your personalised Entitlement and Acceptance Form. Eligible shareholders will comprise those shareholders with a registered address in Australia and New Zealand as at the record date.

The Entitlement Offer is fully underwritten, subject to certain terms and conditions, by Canaccord Genuity (Australia) Limited. Canaccord Genuity (Australia) Limited is also acting as Lead Manager to the Entitlement Offer.

Eligible shareholders should read the Prospectus carefully before making any investment decision regarding the Entitlement Offer. If you are in any doubt about the Entitlement Offer, you should consult your financial or other professional adviser.

The closing date of the Entitlement Offer is Wednesday, 7 September 2022 (unless otherwise extended).

This announcement has been authorised for release by the Board of Directors.

This ASX announcement was approved and authorised by the Board.

==> picture [115 x 27] intentionally omitted <==

Your sincerely

Andrew Metcalfe Company Secretary

For further information please contact:

Alison Coutts David Tasker Managing Director and CEO Managing Director Memphasys Limited Chapter One Advisors T: +61 2 8415 7300 T: +0433 112 936 E: alison.coutts@memphasys.com E: dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations and reproductive biotechnology for high value commercial applications.

Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix[TM] device, combines electrophoresis with proprietary size exclusion membranes to separate sperm cells for human artificial reproduction. Website: www.memphasys.com